Skye Bioscience, Inc.SKYENASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-34.74%
↓ 216% below average
Average (39q)
29.93%
Historical baseline
Range
High:253.20%
Low:-100.00%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -34.74% |
| Q2 2025 | 99.21% |
| Q1 2025 | -7.65% |
| Q4 2024 | 59.59% |
| Q3 2024 | 19.73% |
| Q2 2024 | 109.55% |
| Q1 2024 | 22.30% |
| Q4 2023 | 26.85% |
| Q3 2023 | -29.85% |
| Q2 2023 | 50.94% |
| Q1 2023 | -22.92% |
| Q4 2022 | -13.72% |
| Q3 2022 | 24.84% |
| Q2 2022 | 12.76% |
| Q1 2022 | 13.68% |
| Q4 2021 | 239.72% |
| Q3 2021 | -62.79% |
| Q2 2021 | 44.45% |
| Q1 2021 | 65.09% |
| Q4 2020 | 6.66% |
| Q3 2020 | -19.21% |
| Q2 2020 | -46.41% |
| Q1 2020 | 11.69% |
| Q4 2019 | 39.56% |
| Q3 2019 | -25.44% |
| Q2 2019 | 114.35% |
| Q1 2019 | 35.05% |
| Q4 2018 | 253.20% |
| Q3 2018 | 0.00% |
| Q2 2018 | -100.00% |
| Q1 2018 | -64.29% |
| Q4 2017 | -20.95% |
| Q3 2017 | 46.00% |
| Q2 2017 | -34.15% |
| Q1 2017 | -65.01% |
| Q4 2016 | 226.86% |
| Q3 2016 | -82.49% |
| Q2 2016 | 239.81% |
| Q1 2016 | -60.56% |
| Q4 2015 | 125.38% |